论文部分内容阅读
为了观察吉西他滨联合异环磷酰胺方案二线治疗晚期非小细胞肺癌(NSCLC)的疗效及不良反应,选取24例病理或细胞学确诊的晚期NSCLC,经紫杉类联合铂类化疗方案治疗进展的患者,采用吉西他滨1.0 g/m2,静脉滴入,d1、d8;异环磷酰胺1.2 g/m2,静脉滴入,d2～d4,21 d为1个周期,以TAX317研究结果为历史对照,进行统计分析。可评价疗效24例中,无完全缓解(CR)病例,部分缓解(PR)5例,稳定(SD)12例,进展(PD)7例,有效率21%(5/24),优于TAX317的疗效(6%),化疗不良反应主要是骨髓抑制,3/4度中性粒细胞减少及贫血发生率分别为17%(4/24)及13%(3/24)。初步研究结论提示,吉西他滨联合异环磷酰胺二线治疗晚期NSCLC临床有效,耐受良好,可开展进一步随机对照研究。
In order to observe the efficacy and side effects of gemcitabine combined with ifosfamide in the second-line treatment of advanced non-small cell lung cancer (NSCLC), 24 patients with advanced NSCLC diagnosed by pathology or cytology were enrolled in this study. Patients treated by taxane combined with platinum-based chemotherapy , Using gemcitabine 1.0 g / m2, intravenous infusion, d1, d8; ifosfamide 1.2 g / m2, intravenous infusion, d2 ~ d4, 21 d for a period of TAX317 results for the historical control, statistics analysis. Among the 24 evaluable patients, there were 5 cases of complete remission (CR), 12 cases of partial remission (PR), 12 cases of stable (SD) and 7 cases of progressive (PD). The effective rate was 21% (5/24) (6%). The adverse reactions of chemotherapy were mainly myelosuppression, 3/4 degree neutropenia and anemia rates were 17% (4/24) and 13% (3/24), respectively. Preliminary findings suggest that gemcitabine combined with ifosfamide second-line treatment of advanced NSCLC clinical effective, well tolerated, to carry out further randomized controlled studies.